lazertinib,amivantamab
yuhan corp,oscotec,janssen,genmab
['lazertinib', 'emd']
amivantamab (bispecific ab against egfr &amp; met) + lazertinib (3rd gen egfr tki) have strong activity post osi followed by chemo. really overcomes osi resistance or reflects the effect of rechallenge of an egfr tki? skin tox, infusion related reaction and ild significant. #asco22 
Medical Oncologist - Lung cancer & thymic tumors. Head of Clinical Research @GustaveRoussy - Head of Scientific Chairs Council @EORTC. Tweets are my own.